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Purpose: There are already numerous reports about high local control rates in patients with craniopharyngioma
but there are only few studies with follow up times of more than 10 years. This study is an analysis of long term
control, tumor response and side effects after fractionated stereotactic radiotherapy (FSRT) for patients with
craniopharyngioma.
Patients and methods: 55 patients who were treated with FSRT for craniopharyngioma were analyzed. Median
age was 37 years (range 6–70 years), among them eight children < 18 years. Radiotherapy (RT) was indicated for
progressive disease after neurosurgical resection or postoperatively after repeated resection or partial resection. A
median dose of 52.2 Gy (50 – 57.6 Gy) was applied with typical dose per fraction of 1.8 Gy five times per week. The
regular follow up examinations comprised in addition to contrast enhanced MRI scans thorough physical
examinations and clinical evaluation.
Results: During median follow up of 128 months (2 – 276 months) local control rate was 95.3% after 5 years, 92.1%
after 10 years and 88.1% after 20 years. Overall survival after 10 years was 83.3% and after 20 years 67.8% whereby
none of the deaths were directly attributed to craniopharyngioma. Overall treatment was tolerated well with almost
no severe acute or chronic side effects. One patient developed complete anosmia, another one’s initially impaired
vision deteriorated further. In 83.6% of the cases with radiological follow up a regression of irradiated tumor
residues was monitored, in 7 cases complete response was achieved. 44 patients presented themselves initially with
endocrinologic dysfunction none of them showed signs of further deterioration during follow up. No secondary
malignancies were observed.
Conclusion: Long term results for patients with craniopharyngioma after stereotactic radiotherapy are with respect
to low treatment related side effects as well as to local control and overall survival excellent.
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Craniopharyngioma are rare epithelial solid or mixed
solid-cystic tumors which arise from remnants of the
Rathke pouch mostly in the sellar or suprasellar region.
Despite its benign histological appearance as WHO
grade I tumor they often recur and lead to significant
clinical impairment by compression of structures in
close vicinity such as optic pathways, hypothalamus or
pituitary stalk. Craniopharyngioma account for 1–3% of
all intracranial neoplasm [1] and most commonly present
in children between 5 and 14 years of age or again in
adults between 50 and 75 years [2,3]. Both neurosurgical
and radiotherapeutical approaches are well established in
the treatment of craniopharyngioma however the optimal
treatment strategies are still discussed controversially
[4,5]. Surgery is usually considered the treatment of choice,
especially in children. The extent of microsurgical resection
is most important for long-term local control [6] however
gross total resection often cannot be achieved without
leading to severe hypothalamic-pituitary dysfunction
or visual impairment [7]. Furthermore limited resection
can be necessary to relieve acute symptoms of intracranial
pressure. In the past, radiotherapy (RT) was applied mostly
adjuvant after surgery or in case of recurrence however
there are plenty studies providing data that RT alone is as
effective in respect to local control [8-11]. Since life
expectancy is long local control assumed minimizing
long term treatment related side effects is of highest
priority. Using modern techniques of RT such as fraction-
ated stereotactic radiotherapy (FSRT), stereotactic radio-
surgery (SRS) or treatment with charged particles enables
the delivery of high doses necessary for tumor control
while not exceeding tolerance doses of nearby risk organs
such as the brainstem or optic chiasm and thereby
preventing further endocrinologic or visual deficits;
moreover, reduction of low to medium doses to adjacent
normal tissue can be achieved. In previous studies we
reported of safety and effectiveness of FSRT in patients
with craniopharyngioma [12]. The current study is a
retrospective analysis of updated long-term clinical
outcome and treatment-related side effects with particular
regard to tumor response.
Methods and material
Patient characteristics
We evaluated 55 patients (28 female, 27 male, including
8 children < 18 years) who have been treated between
1989 and 2012 with FSRT for craniopharyngioma at our
institution. Median age was 37 years (range 6 – 70). In
all patients diagnosis was histologically confirmed. The
majority of patients (70.9%, 39 of 55 patients) underwent
RT with tumor progression/recurrence after surgery
rather than adjuvantly after partial resection (29.1%, 16 of
55 patients).Treatment planning
All patients were immobilized by utilizing an individually
manufactured mask system. In most cases an individually
adapted scotch cast mask allowing a repositioning accuracy
of 1 to 2 mm was used [13]. From 1993 on all patients
received both CT and MRI with slice thickness of 3 mm in
mask fixation for treatment planning as described pre-
viously [12]. Before then, only CT scans with stereotactic
localization system were performed. After stereotactic
guided image fusion (gross) target volume (GTV) was
defined on each slice by outlining contrast enhanced
T1-weighted solid lesions as well as all cystic components
and their wall apparent in T2-weighted MRI scans. We
defined the clinical target volume (CTV) for craniophar-
yngioma to be identical with the GTV. For safety reasons
in regard to positioning accuracy a 2 mm margin was
added for planning target volume (PTV). Treatment plan-
ning was performed by using the Stryker-LeibingerSystem
STP, the Virtuos-Software or the Precisis-Software.
Radiotherapy
Radiotherapy was conducted at our institution using linear
accelerators with 6 or 15 megaelectron volts designed for
stereotactic RT. Details on treatment planning and dose
calculation were reported previously at our institution [14].
A median dose of 52.2 Gy (range 50 – 57.6 Gy) was applied
in conventional fractionation with a median single dose of
1.8 Gy (range 1.8 – 2 Gy) 5 times per week using 3–5
individually collimated, non-coplanar, isocentric fields. The
median PTV treated was 31.2 ml (range 6.2 to 138.9 ml).
To account for possible changes of the target volume
MRI scans were performed once during treatment in
asymptomatic patients. In case of new clinical symptoms
CT or MR imaging was performed more frequently.
Radiological assessment
Radiological outcome was classified in five grades by
assessing maximal axial dimension in two orthogonal
directions: complete response (CR) was defined as absence
of detectable tumor residuum on MRI scans. Tumor
diminution of > 50% was assessed as partial response
(PR) and in case of reduction of tumor formation between
25 and 50% as objective response. Change of dimensions of
less than 25% without signs of progression was categorized
as stable disease. Additionally, similar to treatment planning
all solid and cystic components visible on follow up MRI
were taken into consideration and outlined on each slice
separately to gain volumetric information and put them in
relation to the pretherapeutic GTV.
Follow-up
All follow-up appointments consisted of complete phys-
ical examinations and clinical evaluation of endocrino-
logic, ophthalmologic and neurologic status in addition
Figure 1 Median overall survival was 90.3% after 5 years
respectively 83.3% (10 years) and 67.8% (20 years).
Figure 3 No significant difference was observed for progression
free survival whether patients were treated early in the time
course or received RT for tumor recurrence, p-value = 0.37.
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six weeks after completing RT, then patients were seen
every quarter in the first year and every six months in the
following years. Five years after RT intervals were prolonged
to once a year. In case of follow up was continued at
another facility our data was completed by consulting the
attending physicians or contacting the patients themselves.
Acute or chronic treatment related side effects were
classified under the terms of common terminology
criteria of adverse events (CTCAE, v4.043, June 14,Figure 2 Local control rate was 95.3% after 5 years, 92.1% after
10 years and 88.1% after 20 years.2010, available at http://evs.nci.nih.gov/ftp1/CTCAE/
About.html).
Statistical analysis
Overall survival was calculated from the time of first
diagnosis up to the last follow-up visit or death by
any cause. Local control rate was calculated from the
onset of radiotherapy using the Kaplan-Meier method.
(Sigma Plot, Systat Software GmbH).
Results
Radiotherapy
Radiotherapy was completed in all 55 patients as intended.
39 patients underwent treatment because of recurrent or
progressive craniopharyngioma after initial resection. The
mean time between surgery and begin of radiotherapy was
40.7 months (range 6 – 256 months). Due to hydrocephalus
after cyst enlargement treatment had to be interrupted
in one patient after only two fractions. With a newly
implanted ventriculo-peritoneal shunt in place and
updated postoperative cerebral imaging treatment was
replanned and could be continued without further
complications. Apart from this case there were no
other significant adverse events or incidents exceeding
grade I according to CTCAE.
Follow up
Median follow up time was 128 months (range 2 –
276 months). During this period two female patients
(29 years, 51 years) presented with signs of shunt insuffi-
ciency three and 49 months after RT necessitating
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of the craniopharyngioma could be seen by means of
MRI. Due to perioperative complications one patient
died after only two months of follow up and the other’s
general condition deteriorated that no further MRI scans
were performed hence the patient was censored after
49 months dying 88 months after RT. A third 25 year
old female patient developed 21 months after RT focal
neurological deficits, nausea and emesis as well due to
shunt insufficiency. Once the ventriculo-peritoneal shunt
was replaced the symptoms disappeared and no further
interventions were necessary. At her last follow-up she
was in good general condition with stable disease.
After receiving FSRT improvement of visual impairment
was notable in six patients and only one 56 year old
female patient who developed mild decrease of visual acu-
ity. Prior to RT 44 patients suffered from endocrinopathies.
It is worth mentioning that all patients had intact hormone
function at the time of initial diagnosis and developed
endocrinological deficiencies only postoperatively.
One 50 year old male patient reported during follow up
of progredient loss of sense of smell leading to complete
anosmia 26 months after RT. Impairment of cognitive
function did not occur however formal neuropsycho-
logical testing was not performed. Assessment of neurologicFigure 4 Comparison of representative sagittal, coronar and transversa
female patient before (a) and six months after radiotherapy (b): a subst
only small residues.impairment was based on information provided by the
patients and their home physicians e.g. whether change in
social behavior appeared or special educational needs were
required. Furthermore no severe treatment related long
term side effects were observed, especially no case of
radionecrosis or secondary malignancies.
Median overall survival was 90.3% after 5 years respect-
ively 83.3% (10 years) and 67.8% (20 years) whereby none
of the deaths were directly attributed to craniopharyngioma
(Figure 1). Local control rate was 95.3% after 5 years, 92.1%
after 10 years and 88.1% after 20 years (Figure 2). There
was no significant difference notable when overall survival
was calculated in regard to adjuvant RT opposed to RT in
case of progression, p-value = 0.37 (Figure 3).
Radiological assessment
After six months in 83.6% of the cases with radiological
follow up a regression of irradiated tumor residues
was monitored, in eight cases complete response was
achieved (Figure 4, Table 1). Additionally, where available
images from restaging MRI were uploaded to treatment
planning system and GTV was again defined by out-
lining contrast enhanced T1-weighted solid lesions as
well as all cystic components and their wall apparent
in T2-weighted MRI scans allowing an assessment ofl images from pre- and posttherapeutic MR scans of a 56 year-old
antial decrease of the solid-cystic tumor can be detected leaving
Table 1 Radiological outcome 6 months after
radiotherapy (as defined in methods and material)
Complete response 7 patients
Partial response 34 patients
Objective response 8 patients
Stable disease 5 patients
Progress 1 patient
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craniopharyngioma with FSRT led to a median volume
reduction of 60.8%.
Discussion
Our study shows that long term outcome for patients with
craniopharyngioma after being treated with FSRT is excel-
lent as low treatment related side effects is concerned as
well as local control rate and overall survival.
Optimal treatment strategy for craniopharyngioma has
been subject to debate for a long time and is still
discussed controversially [6,12,15,16]. In the past, the
recommended therapeutical approach consisted of
attempted complete resection. However the tumor’s
vicinity to vital structures such as the hypothalamus
or the optic chiasm posed a major challenge for
achieving this goal without inflicting severe morbidity
[17,18]. Even with advances of neurosurgical techniques
such as implementation of microsurgery a primarily gross
total resection is often associated with poor results with
regard to endocrinological or neurocognitive outcome
[7,19]. In recent years less radical surgical approaches in
combination with adjuvant treatment established [20].
Especially in cases of subtotal resection RT has been
performed with similar results in terms of local control
and overall survival [21,22]. However each strategy
has its distinct treatment related risk profile; neurosurgical
resection is associated with acute complications whereas
RT-induced side effect may occur only after many years.
There is controversial discussion about the optimal
dose for craniopharyngioma. As it is a benign disease,Figure 5 Exemplary dose volume histogram of a FSRT plan with a pro
reducing especially long-term side effects can be achieved.one is reluctant to apply high doses. However a total
dose of > 54 Gy is recommended for external radiation
using conventional techniques with excessively rising
recurrence rates for doses < 54 Gy [23]. Limitations are
posed by the tolerance doses of vital organs in the vicinity.
Therefore, commonly doses between 50.4 – 54 Gy are
applied, depending on the volume of the lesion, the
anatomical pattern, pretreatment factors as well as
physician and center preference. Technical advances
and modern techniques such as FSRT deliver means
for applying high doses to a specific target while sparing
the surrounding risk organs. In addition fractionation
causes further radiobiological advantages concerning
treatment-related adverse reactions [24]. Previous analysis
of 40 patients at our institution resulted in excellent local
control of 100% and overall survival of 89% after
10 years [12]. Similar findings were reported in other
studies [25,26]. Since life expectancy for patients with
craniopharyngioma after receiving treatment is barely
limited the reduction of long term treatment-related
side effects is of highest relevance. Our long term
follow-up of 128 months combined with low rates of
acute and chronic side effects reinforces the role of FSRT
in the management of craniopharyngioma. Considering
the excellent long-term prognosis it can be argued if
further improvement by proton therapy is possible. With
protons, low doses are deposited within the entry channel
of the beam, and high local dose deposition can be
achieved within the Bragg peak. Due to these physical
properties, reduction of integral dose is possible (Figure 5)
potentially reducing especially long-term side effects, such
as neurocognitive dysfunctioning, hormonal deficiency
and secondary malignancies even more.
Yet the point in time of RT is still disputed. Should RT
be reserved for tumor recurrence or rather be administered
at first diagnosis not least because of excellent functional
outcome? Regimen et al. reported of improved overall
survival when treated primarily [27]. Moon et al. recently
suggested comparable results in overall survival for
adjuvant RT, early or late [28]. Similar findings were madeton beam. Significant reduction of integral dose and thereby potentially
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provide the evidence that FSRT is a safe and effective
treatment option for achieving long term control
without inflicting severe functional or hormonal impair-
ment. Whether patients were treated early in the time
course or received RT for tumor recurrence did not seem
to make a difference for local control, overall survival or
neurocognitive function.
With FSRT a reduction of safety margins is possible,
thereby leading to a smaller PTV and sparing of normal
tissue [30]. The main rationale for target volume reduction
is to decrease radiation induced long term complication
such as secondary malignancies or impaired cognitive
function. Particle therapy with protons offer several
potential biological and physical advantages such as
inverse depth dose profile leading to a steep dose gradient
around the target volume. Thereby especially the low and
medium dose regions could be minimized. Fitzek et al. pre-
sented an analysis of 15 patients treated with a combination
of photon and proton irradiation for craniopharyngioma
resulting in local control rates and overall survival compar-
able to other contemporary investigations [31]. However
the risk of new cyst formation and therewith alteration of
PTV has to be taken into consideration for proton therapy.Conclusion
FSRT leads to excellent results in patients with cranio-
pharyngioma regarding local control, overall survival
and preservation of organ function. Proton therapy
may be able to further enhance the risk-benefit profile.
Interdisciplinary treatment of these patients, especially in
pediatric age, is strongly recommended to optimally
decide on the sequence between wait-and-scan, surgery
and/or radiation therapy.Consent
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